United States

The claim that over-patenting hinders the development of new treatments is not supported by the evidence, says the US Biotechnology Industry Organization.

The US biotechnology industry has gone through more than three years of sustained IPO financings, but that news isn’t all rosy for the industry.

The days of medical charities passively handing out grants and waiting to hear of any results are over. Now the money comes attached to sophisticated, target-driven deals.

Leading researchers seeking to stave off modern plagues are making progress in understanding the mechanisms of diseases such as influenza and anthrax.

The value of R&D coming out of US universities is increasing. And the question of exactly how Europe measures up in comparison may soon be answered.

Europe has staked its future on building a knowledge economy. But once again, a major R&D investment by one of its leading companies is going to the US.

Matching consumer demand with R&D may seem like an obvious starting point for innovation. But it has proven a transient goal for many countries and companies.